#Taiwan #New Taipei City #Caliway Biopharmaceuticals #TWSE-6919 #FTSE TWSE

Caliway Biopharmaceuticals Allies with FTSE TWSE Indices

NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ — Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in two notable indices: the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index. This development, which takes effect on December 23, 2024, underscores Caliway's rising prominence in the biopharmaceutical sector and its growing influence within the global biotech arena.

The FTSE TWSE Taiwan Mid-Cap 100 Index, launched in 2004, is designed to track the top 100 mid-cap companies in Taiwan based on market capitalization, deliberately omitting the largest 50 companies from the FTSE TWSE Taiwan 50 Index. This index tends to spotlight dynamic sectors that are ripe for growth, and Caliway’s inclusion indicates its potential and aspirations toward expansion.

On the other hand, the FTSE TWSE Taiwan Eight Industries Index, introduced in 2007, focuses on the performance of Taiwan’s eight primary industrial sectors. The firms represented in this index are chosen for their strong standings in their respective industries, making it a powerful affirmation of Caliway's leadership within Taiwan’s thriving biopharmaceutical landscape.

Achieving inclusion in these indices signifies a robust performance in the market, promising growth trajectories and higher visibility among investors, both locally and internationally. Caliway is committed to advancing innovative biopharmaceutical solutions, and this recognition aligns perfectly with its goal to deliver groundbreaking therapeutic alternatives while creating significant value for its stakeholders.

Caliway Biopharmaceuticals is positioned to further its impact in the biopharmaceutical field, leveraging its forward-thinking pipeline and strong market stature. The company aims not just to participate in the industry evolution in Taiwan but also on a global scale.

About the FTSE TWSE Taiwan Index Series

The FTSE TWSE Taiwan Index Series is a collaborative effort between the Taiwan Stock Exchange Corporation (TWSE) and FTSE Russell. It provides market participants with a comprehensive set of tools to engage with the Taiwanese market effectively. These indices serve as benchmark tools for trading derivatives, assessing performance, and managing investment portfolios through exchange-traded funds (ETFs).

About Caliway Biopharmaceuticals

Founded as a clinical-stage biopharmaceutical company, Caliway Biopharmaceuticals (TWSE-6919) prioritizes the development of cutting-edge therapeutics aimed at redefining patient outcomes via innovation.

Disclaimer

This content includes forward-looking statements that carry inherent risks and uncertainties. Actual results may differ materially from those projected in these statements. The company does not assume any obligation to update the information herein as circumstances evolve.

To learn more about Caliway Biopharmaceuticals, visit www.caliway.com.tw or Taiwan Index.